937 results on '"Laskin, J."'
Search Results
52. ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
53. Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location
54. MA14.07 The Impact of Socioeconomic Status and Geographic Location on Palliative Chemotherapy Uptake in Patients with Metastatic NSCLC
55. MA02.11 Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE)
56. P2.13-13 Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis
57. Clinical benefit of whole genome and transcriptome analysis (WGTA) in metastatic colorectal cancer (MCRC): Results from the personalized oncogenomics program (POG)
58. MA14.05 Social Isolation Increases Psychological Distress in Patients With NSCLC
59. Inhibition of ozone-induced nitric oxide synthase expression in the lung by endotoxin.
60. Inhibition of macrophages with gadolinium chloride abrogates ozone-induced pulmonary injury and inflammatory mediator production.
61. Enhanced production of interleukin-1, tumor necrosis factor-alpha, and fibronectin by rat lung phagocytes following inhalation of a pulmonary irritant.
62. Production of nitric oxide by rat type II pneumocytes: increased expression of inducible nitric oxide synthase following inhalation of a pulmonary irritant.
63. Personalized oncogenomics in the management of gastrointestinal carcinomas&mdash
64. OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays
65. P1.03-020 Detection of Hypoxia Using EF5 PET/CT in 10 Patients with Advanced NSCLC Receiving Chemotherapy with and without Bevacizumab
66. P3.01-019 Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing
67. P3.01-062 The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing
68. MA 04.02 Assessing the Psychosocial Needs of Newly Diagnosed NSCLC Patients: Identifying the Population Most At-Risk
69. Kinetic energy release distributions and evaporation energies for metastable fullerene ions
70. Kinetic energy release for metastable fullerene ions
71. Mass spectrometric study of unimolecular decompositions of endohedral fullerenes
72. Electrolytic Hydrogen Generators
73. Regulation of lung macrophage activation following irritant-induced injury by farnesoid X receptor FXR
74. 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
75. Carcinoma Ex Pleomorphic Adenoma: Case Report and Options for Systemic Therapy
76. Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
77. 440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
78. 440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7)
79. Clinicians identify high need to increase their genomic literacy to applied cancer genomics
80. Availability of tumour gene expression data facilitates clinical decision-making for patients with advanced cancers
81. Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
82. Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
83. High-resolution mass spectrometry and molecular characterization of aqueous photochemistry products of common types of secondary organic aerosols
84. Self-consistent determination of fullerene binding energies BE (C+n–C2), n=58· · ·44.
85. P-291 - NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option
86. 466O - ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
87. 410P - FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive behavior: Clinical and molecular pathology findings of two cases
88. 1583P - Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location
89. 585P - Clinical benefit of whole genome and transcriptome analysis (WGTA) in metastatic colorectal cancer (MCRC): Results from the personalized oncogenomics program (POG)
90. Integration of a Nurse Navigator into the Triage Process for Patients with Non-Small-Cell Lung Cancer: Creating Systematic Improvements in Patient Care
91. Supplementary material to "Molecular transformations of phenolic SOA during photochemical aging in the aqueous phase: competition among oligomerization, functionalization, and fragmentation"
92. Molecular transformations of phenolic SOA during photochemical aging in the aqueous phase: competition among oligomerization, functionalization, and fragmentation
93. 232 Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology
94. Histologic Classification of Non-Small-Cell Lung Cancer over Time: Reducing the Rates of Not-Otherwise-Specified
95. Role of Bone Marrow Derived Macrophages in Acetaminophen‐induced Injury
96. Bone Marrow and Spleen as Sources of Inflammatory Macrophages Responding to Ozone‐Induced Lung Injury
97. Chemical characterization of SOA formed from aqueous-phase reactions of phenols with the triplet excited state of carbonyl and hydroxyl radical
98. Using pet-ct to Reduce Futile Thoracotomy Rates in Non-Small-Cell Lung Cancer: A Population-Based Review
99. 2060 - Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
100. Practical Guidelines for Ethical and Policy Issues that Arise from the Clinical Application of Whole Genome Sequencing in Cancer Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.